抗毒素市場規模、佔有率和成長分析（按抗毒素類型、生物種類、作用機制、最終用戶和地區）- 2025-2032 年產業預測

2023 年抗毒素市場規模價值 21 億美元，預計將從 2024 年的 22.7 億美元成長到 2032 年的 42.3 億美元，預測期間（2025-2032 年）的複合年成長率為 8.1%。

由於蛇咬傷發生率的上升和對有效治療方法的認知的提高，全球抗蛇毒血清市場正在經歷顯著成長。蛇咬傷仍然是一個主要的公共衛生問題，特別是在有毒物種流行的地區，如撒哈拉以南非洲、南亞和東南亞。根據世界衛生組織統計，蛇咬傷每年導致數萬人死亡，許多倖存者遭受長期殘疾。政府、非政府組織和醫療保健提供者正在積極改善抗蛇毒血清的取得途徑並促進其生產和分發。生物技術的進步促進了更安全、更有效的製劑的開發，改善了治療效果。然而，高成本、缺乏標準化和製造流程複雜等挑戰阻礙了市場擴張，特別是在負擔能力是一個主要問題的低收入地區。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步
• 貿易分析

抗毒素市場規模（按抗毒素類型）

• 市場概況
• 多效價
• 單一值
• 其他

抗毒素市場規模（按物種分類）

• 市場概況
• 抗蛇毒血清
• 蝎子抗蛇毒血清
• 蜘蛛抗蛇毒血清
• 其他

抗毒素市場規模（按作用機制）

• 市場概況
• 細胞毒性
• 神經毒性
• 血液學毒性
• 心臟毒性
• 肌肉毒性
• 其他

抗毒素市場規模（按最終用戶分類）

• 市場概況
• 醫院和診所
• 門診手術中心
• 研究組織
• 其他

抗毒素市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• BTG plc（United Kingdom）
• Laboratorios Silanes（Mexico）
• CSL Limited（Australia）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• Bharat Serums and Vaccines Limited（India）
• Haffkine Bio-Pharmaceutical Corporation Ltd（India）
• Boehringer Ingelheim International GmbH（Germany）
• Rare Disease Therapeutics Inc.（United States）
• South African Vaccine Producers（Pty）Ltd（South Africa）
• Instituto Butantan（Brazil）
• Instituto Clodomiro Picado（Costa Rica）
• Vins Bioproducts Limited（India）
• MicroPharm Limited（United Kingdom）
• Protherics PLC（United Kingdom）
• Inosan Biopharma（Spain）
• Sanofi Pasteur（France）
• Serum Institute of India Pvt. Ltd.（India）
• Bio-Pharmaceutical Corporation Ltd.（China）
• Thai Red Cross Society（Thailand）

結論和建議

Anti-Venom Market size was valued at USD 2.1 billion in 2023 and is poised to grow from USD 2.27 billion in 2024 to USD 4.23 billion by 2032, growing at a CAGR of 8.1% during the forecast period (2025-2032).

The global anti-venom market is experiencing significant growth, driven by the rising incidence of snakebites and increasing awareness of effective treatment options. Snakebites remain a major public health concern, particularly in regions such as Sub-Saharan Africa, South Asia, and Southeast Asia, where venomous species are prevalent. According to WHO, snakebites cause tens of thousands of deaths annually, with many survivors suffering long-term disabilities. Governments, NGOs, and healthcare providers are actively improving access to anti-venom, boosting production and distribution. Advancements in biotechnology have led to safer and more effective formulations, enhancing treatment outcomes. However, challenges such as high costs, lack of standardization, and complex production processes continue to hinder market expansion, particularly in low-income regions where affordability remains a critical issue.

Top-down and bottom-up approaches were used to estimate and validate the size of the Anti-Venom Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Anti-Venom Market Segments Analysis

Global Anti-Venom Market is segmented by Anti-venom Type, Species Type, Mode of Action, End User and region. Based on Anti-venom Type, the market is segmented into Polyvalent, Monovalent and Others. Based on Species Type, the market is segmented into Snake Antivenom, Scorpion Anti-venom, Spider Anti-venom and Others. Based on Mode of Action, the market is segmented into Cytotoxic, Neurotoxic, Haemotoxic, Cardiotoxic, Myotoxic and Others. Based on End User, the market is segmented into Hospitals & clinics, Ambulatory Surgical Centers, Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Anti-Venom Market

Our analysis reveals that the growing incidence of snakebite cases globally is a crucial factor driving the expansion of the anti-venom market. Snakebites pose a severe public health challenge, particularly in regions with dense snake populations, such as parts of Asia, Africa, and Latin America. The World Health Organization (WHO) classifies snakebite envenomation as a neglected tropical disease, emphasizing the urgent need for effective treatments. Rising awareness, improved healthcare access, and government initiatives to provide life-saving anti-venom therapies are further propelling market growth. As snakebite cases continue to surge, the demand for reliable and affordable anti-venom solutions is expected to rise.

Restraints in the Anti-Venom Market

Our analysis reveals that inadequate healthcare infrastructure and logistical challenges in remote or rural areas significantly restrain the growth of the global anti-venom market. Limited access to medical facilities and a lack of proper cold chain storage for anti-venom distribution hinder its timely availability, increasing the risk of fatality and severe complications among snakebite victims. Additionally, transportation difficulties and insufficient trained healthcare personnel further exacerbate the issue, delaying critical treatment. These barriers contribute to uneven market penetration, limiting the adoption of anti-venom therapies in regions where snakebites are prevalent, ultimately affecting the overall market growth and accessibility of life-saving treatments.

Market Trends of the Anti-Venom Market

Our analysis reveals that increasing awareness and education campaigns are emerging as a key trend in the Global Anti-Venom Market. Governments, healthcare organizations, and non-profits are actively launching initiatives to educate healthcare professionals, communities, and individuals about snakebite prevention, early recognition, and appropriate treatment. These programs aim to reduce mortality and morbidity associated with venomous bites by improving response times and access to medical intervention. Additionally, digital platforms, workshops, and community outreach efforts are enhancing public knowledge and preparedness, ultimately driving demand for anti-venom products and supporting the market's growth through improved treatment accessibility and effectiveness.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis

Global Anti-Venom Market Size by Anti-venom Type & CAGR (2025-2032)

• Market Overview
• Polyvalent
• Monovalent
• Others

Global Anti-Venom Market Size by Species Type & CAGR (2025-2032)

• Market Overview
• Snake Antivenom
• Scorpion Anti-venom
• Spider Anti-venom
• Others

Global Anti-Venom Market Size by Mode of Action & CAGR (2025-2032)

• Market Overview
• Cytotoxic
• Neurotoxic
• Haemotoxic
• Cardiotoxic
• Myotoxic
• Others

Global Anti-Venom Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & clinics
• Ambulatory Surgical Centers
• Research Institutes
• Others

Global Anti-Venom Market Size & CAGR (2025-2032)

• North America (Anti-venom Type, Species Type, Mode of Action, End User)
  • US
  • Canada
• Europe (Anti-venom Type, Species Type, Mode of Action, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Anti-venom Type, Species Type, Mode of Action, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Anti-venom Type, Species Type, Mode of Action, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Anti-venom Type, Species Type, Mode of Action, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• BTG plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratorios Silanes (Mexico)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Serums and Vaccines Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haffkine Bio-Pharmaceutical Corporation Ltd (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rare Disease Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• South African Vaccine Producers (Pty) Ltd (South Africa)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instituto Butantan (Brazil)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instituto Clodomiro Picado (Costa Rica)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vins Bioproducts Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MicroPharm Limited (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protherics PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inosan Biopharma (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Pasteur (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Serum Institute of India Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Pharmaceutical Corporation Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thai Red Cross Society (Thailand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations